Core Insights - Flux Power Holdings, Inc. reported a quarterly loss of $0.14 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.04, marking an earnings surprise of -250.00% [1] - The company's revenues for the quarter ended September 2025 were $13.18 million, missing the Zacks Consensus Estimate by 20.1%, and down from $16.13 million a year ago [2] - The stock has increased approximately 50% since the beginning of the year, outperforming the S&P 500's gain of 16.5% [3] Financial Performance - Over the last four quarters, Flux Power has surpassed consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $17.59 million, and for the current fiscal year, it is -$0.03 on revenues of $73.08 million [7] Market Outlook - The company's earnings outlook will be crucial for future stock performance, with management's commentary on the earnings call being a key factor [4] - The Zacks Rank for Flux Power is currently 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] - The Electronics - Miscellaneous Products industry, to which Flux Power belongs, is currently in the top 14% of Zacks industries, suggesting a favorable industry outlook [8]

Core Insights - RenovoRx, Inc. reported a quarterly loss of $0.08 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.10 per share a year ago [1] - The company generated revenues of $0.27 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 35.12%, while revenues were zero a year ago [2] - RenovoRx shares have declined approximately 22.5% year-to-date, contrasting with the S&P 500's gain of 16.5% [3] Company Performance - The earnings outlook for RenovoRx is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.08 on revenues of $0.48 million, and -$0.31 on revenues of $1.51 million for the current fiscal year [7] - The company has surpassed consensus EPS estimates only once in the last four quarters [1] Industry Context - The Medical - Biomedical and Genetics industry, to which RenovoRx belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact RenovoRx's stock performance [5]

Bitfarms Ltd. (BITF) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this company would post a loss of $0.01 per share when it actually produced a loss of $0.02, delivering a surprise of -100%.Over the last four quarters, the company has surpassed consensus EPS estimates just once.Bitfarms, which belongs to the Zacks Techn ...

Core Insights - Anterix reported a quarterly loss of $0.14 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.65, marking an earnings surprise of +78.46% [1] - The company achieved revenues of $1.55 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 9.30% [2] - Anterix has consistently surpassed consensus EPS estimates over the last four quarters, achieving this four times [2] Financial Performance - The loss per share improved from $0.69 a year ago to $0.14 this quarter, indicating a positive trend in financial performance [1] - The company has topped consensus revenue estimates only once in the last four quarters, despite the recent positive revenue report [2] Stock Performance and Outlook - Anterix shares have declined approximately 41.3% year-to-date, contrasting with the S&P 500's gain of 16.4% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.61 on revenues of $1.43 million, and -$0.47 on revenues of $5.71 million for the current fiscal year [7] Industry Context - The Communication - Infrastructure industry, to which Anterix belongs, is currently ranked in the top 16% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Historical data indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1, highlighting the potential for industry influence on stock performance [8]

分组1 - CuriosityStream Inc. reported a quarterly loss of $0.06 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.02, marking an earnings surprise of -200.00% [1] - The company posted revenues of $18.36 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 12.98%, and showing an increase from $12.6 million year-over-year [2] - CuriosityStream shares have increased approximately 145.1% since the beginning of the year, significantly outperforming the S&P 500's gain of 16.4% [3] 分组2 - The earnings outlook for CuriosityStream is uncertain, with current consensus EPS estimates at -$0.03 for the coming quarter and -$0.04 for the current fiscal year, alongside revenues of $17.66 million and $68.01 million respectively [7] - The Zacks Industry Rank indicates that the Film and Television Production and Distribution sector is currently in the bottom 9% of over 250 Zacks industries, suggesting potential underperformance compared to higher-ranked industries [8] 分组3 - The estimate revisions trend for CuriosityStream was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] - The company has surpassed consensus revenue estimates four times over the last four quarters, but has only exceeded consensus EPS estimates once [2]

Core Insights - Journey Medical Corporation reported a quarterly loss of $0.09 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.08, but an improvement from a loss of $0.12 per share a year ago, indicating a -12.50% earnings surprise [1] - The company generated revenues of $17.63 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 0.39%, but showing growth from $14.63 million in the same quarter last year [2] - Journey Medical shares have increased approximately 131.5% year-to-date, significantly outperforming the S&P 500's gain of 16.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $19.5 million, and for the current fiscal year, it is -$0.42 on revenues of $68.15 million [7] - The estimate revisions trend for Journey Medical was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Medical - Drugs industry, to which Journey Medical belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - GrowGeneration (GRWG) reported a quarterly loss of $0.04 per share, better than the Zacks Consensus Estimate of a loss of $0.09, marking an earnings surprise of +55.56% [1] - The company posted revenues of $47.25 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 13.09%, although this represents a decline from $50.01 million in the same quarter last year [2] - The stock has underperformed the market, losing about 13% year-to-date compared to the S&P 500's gain of 15.6% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $39.11 million, and for the current fiscal year, it is -$0.41 on revenues of $157.56 million [7] - The estimate revisions trend for GrowGeneration was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - GrowGeneration operates within the Zacks Agriculture - Products industry, which is currently ranked in the top 41% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - The performance of GrowGeneration's stock may be influenced by the overall industry trends, as empirical research indicates a strong correlation between near-term stock movements and earnings estimate revisions [5]

Core Viewpoint - Sweetgreen, Inc. reported a quarterly loss of $0.27 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.18, marking a 50% earnings surprise to the downside [1] - The company has consistently missed consensus EPS estimates over the last four quarters [2] Financial Performance - Sweetgreen's revenues for the quarter ended September 2025 were $172.39 million, falling short of the Zacks Consensus Estimate by 4.23% and down from $173.43 million year-over-year [2] - The company has only surpassed consensus revenue estimates once in the last four quarters [2] Stock Performance - Sweetgreen shares have declined approximately 79.8% since the beginning of the year, contrasting sharply with the S&P 500's gain of 15.6% [3] Future Outlook - The company's earnings outlook is critical for assessing future stock performance, with current consensus EPS estimates at -$0.23 for the upcoming quarter and -$0.74 for the current fiscal year [4][7] - The Zacks Rank for Sweetgreen is currently 4 (Sell), indicating expectations of underperformance in the near future [6] Industry Context - The Retail - Restaurants industry, to which Sweetgreen belongs, is currently ranked in the bottom 12% of over 250 Zacks industries, suggesting a challenging environment [8] - Empirical research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than a factor of 2 to 1 [8]

Core Insights - B&G Foods, Inc. reported better-than-expected earnings for Q3 fiscal 2025 despite ongoing top-line pressures, with adjusted earnings of 15 cents per share, up 15.4% from 13 cents in the previous year [3][10] - The company experienced a 4.7% year-over-year decline in net sales to $439.3 million, primarily due to lower volumes and unfavorable foreign exchange, although improved pricing and product mix provided some offset [3][4] Financial Performance - Adjusted EBITDA remained steady at $70.4 million, with an adjusted EBITDA margin improvement from 15.3% to 16% [5] - SG&A expenses decreased by 3% year over year to $44.6 million, while as a percentage of sales, SG&A rose slightly to 10.2% [5] - The adjusted gross profit was $98.8 million, down from $102.4 million in the year-ago period, but the adjusted gross margin expanded by 30 basis points to 22.5% [4] Segment Performance - Specialty segment net sales fell 6.5% to $150.5 million, with adjusted EBITDA dropping 8.7% to $37.7 million [6] - Meals segment net sales dipped 1.4% to $110 million, while adjusted EBITDA grew 2.7% to $23.9 million [6] - Frozen & Vegetables segment saw a 13.2% drop in net sales to $77.4 million, but adjusted EBITDA surged to $4.2 million from $1.2 million [7] - Spices & Flavor Solutions segment net sales rose 2.1% to $101.4 million, although adjusted EBITDA decreased 7.4% to $26.4 million due to higher raw material costs [8] Financial Health - B&G Foods ended the quarter with cash and cash equivalents of $60.9 million, net long-term debt of $2,020.4 million, and total shareholders' equity of $470.7 million [9] Outlook - The company narrowed its fiscal 2025 outlook, projecting net sales between $1.82 billion and $1.84 billion, adjusted EBITDA of $273 million to $280 million, and adjusted earnings per share in the range of 50-58 cents [11]

Teads Holding Co. (TEAD) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to earnings of $0.11 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -13.33%. A quarter ago, it was expected that this company would post a loss of $0.13 per share when it actually produced a loss of $0.1, delivering a surprise of +23.08%.Over the last four quarters, the company has s ...